S-1/A: Windtree Therapeutics Files Amendment No. 2 to Form S-1, Registering Shares for Resale

Windtree Therapeutics is registering up to 31,247,383 shares of common stock for resale by selling stockholders, including shares issuable upon conversion of preferred stock, exercise of warrants, and under an equity line of credit agreement.

Summary

• Windtree Therapeutics filed an Amendment No. 2 to its Form S-1 registration statement on April 24, 2025, to register the resale of up to 31,247,383 shares of its common stock.
• The shares include (i) up to 8,053,565 shares issuable upon conversion of Series C convertible preferred stock, (ii) up to 440,583 shares issuable upon exercise of certain warrants, (iii) up to 919,132 shares issuable upon conversion of 20% OID Senior Secured Promissory Notes, and (iv) up to 21,834,103 shares issuable under an equity line of credit (ELOC) agreement with Seven Knots, LLC.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, except for potential proceeds from the exercise of warrants (up to approximately $0.2 million) and sales of ELOC shares to Seven Knots (up to $23.8 million).
• Windtree has already received $11.2 million from the issuance of 342,900 shares under the ELOC Purchase Agreement.
• The last reported sale price of Windtree's common stock on The Nasdaq Capital Market on April 23, 2025, was $1.13 per share.
• A 1-for-50 reverse stock split was effectuated on February 20, 2025, and trading began on a split-adjusted basis on February 21, 2025.
• The company is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are potential opportunities for raising capital and a new corporate strategy, the company's financial situation is concerning due to its history of operating losses, accumulated deficit, and dependence on securing additional funding. The registration of shares for resale also introduces the risk of dilution.

Positives

• The company has the potential to raise additional capital through the exercise of warrants and the ELOC agreement.
• The ELOC agreement provides a committed source of equity financing.
• The company has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas, potentially enabling them to leverage synergies and optimize commercial performance across future subsidiaries.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling stockholders, except for potential proceeds from the exercise of warrants and sales of ELOC shares.
• The company has a history of operating losses and an accumulated deficit of $846.6 million as of December 31, 2024.
• The company's ability to advance its development programs is dependent upon its ability to secure additional capital.
• The company's current cash and cash equivalents were $1.8 million as of December 31, 2024, with current liabilities of $5.7 million.

Risks

• The company's ability to advance its development programs is dependent upon its ability to secure additional capital.
• Sales of a substantial number of shares of common stock by the selling stockholders could cause the price of the company's common stock to decline.
• Future equity offerings and other issuances of the company's securities could result in dilution to existing stockholders.
• The company may use proceeds from sales of its common stock in ways with which investors may not agree or in ways which may not yield a significant return.
• Seven Knots will pay less than the then-prevailing market price for the company's common stock, which could cause the price of the company's common stock to decline.
• The company's inability to access a portion or the full amount available under the ELOC Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on its business or results of operation.

Future Outlook

The company plans to continue to incur significant research and clinical development, regulatory, and other expenses as it continues to develop its product candidates, seeks regulatory clearances or approvals, conducts clinical trials, and manufactures, markets, and sells any product candidates for which it may obtain regulatory approval. The company also plans to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline.

Management Comments

• The Company will seek acquisition targets to achieve the Company's new corporate strategy.
• The Company will seek to use equity to acquire subsidiaries.

Industry Context

The document highlights Windtree's strategy to acquire small biotech companies with FDA-approved products, which reflects a trend of consolidation in the biotech industry where larger companies acquire smaller ones to expand their product portfolios and leverage commercialization expertise. This strategy is aimed at addressing the challenges faced by many small biotech companies in maximizing the commercial potential of their approved products.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• However, the strategy of acquiring smaller biotech companies with approved products is a common practice in the pharmaceutical industry, with companies like Pfizer, Johnson & Johnson, and Novartis frequently engaging in such acquisitions to bolster their pipelines and revenue streams.
• The success of this strategy depends on the valuation and growth potential of the acquired companies, as well as Windtree's ability to integrate and commercialize their products effectively.

Related Party Transactions

• The company entered into an ELOC Purchase Agreement with Seven Knots, LLC, whereby Seven Knots has agreed to purchase from the company, from time to time, shares of the company's common stock having a total maximum aggregate purchase price of $35.0 million.
• Seven Knots also purchased a Subject Note in an initial principal amount of $156,250.
• Craig Fraser, former President and Chief Executive Officer and a member of the board of directors, resigned from the board of directors on April 17, 2025.
• Steven Simonson, M.D., has served as the company's Senior Vice President and Chief Medical Officer since April 2017.
• The company has engaged Ladenburg Thalmann & Co. Inc. as its exclusive placement agent in connection with warrant exercise inducement offer letters and as the sole underwriter in connection with a public offering of shares of common stock and warrants.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees' job security may be affected by the company's financial situation and strategic decisions.
• Customers may benefit from the development and commercialization of new products.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company will continue to develop its product candidates.
• The company will seek regulatory clearances or approvals for its product candidates.
• The company will conduct clinical trials on its product candidates.
• The company will manufacture, market, and sell any product candidates for which it may obtain regulatory approval.
• The company will seek acquisition targets to achieve its new corporate strategy.
• An unblinded review of the data from the first 20 subjects in the SEISMiC C Study is planned to take place in Q3 2025.
• Enrollment in the SEISMiC C Study is anticipated to be completed in Q1 2026.

Key Dates

Keywords

common stock, resale, preferred stock, warrants, ELOC, equity line of credit, istaroxime, financing, biotechnology, Windtree Therapeutics